Blog
21 February 2026
Exploring BDCA2 Inhibition: A New Hope for Cutaneous Lupus Treatment
Discover the potential of BDCA2 inhibition in treating cutaneous lupus erythematosus with litifilimab. Explore new therapeutic advancements and patient insights.
Read more
Understanding Short-Term Systemic Corticosteroids in Atopic Dermatitis Care
Discover essential insights on short-term systemic corticosteroids in atopic dermatitis care. Learn about risks, benefits, and expert guidance for effective...
21 02 2026
Read more
Innovative Approach to Chronic Urticaria: Targeting MRGPRX2 Explained
Discover an innovative treatment for chronic urticaria targeting MRGPRX2. Explore phase 1 data on SEP-631 and its potential to improve...
21 02 2026
Read more
Revolutionizing Skin Health: The Rise of Regenerative Medicine in Dermatology
Discover how regenerative medicine is transforming dermatology, enhancing skin health, and reshaping medical and aesthetic practices. Learn more now!
20 02 2026
Read more
Revolutionizing Atopic Dermatitis Treatment with Gene Expression Insights
Discover how gene expression insights are revolutionizing atopic dermatitis treatment, offering personalized solutions for effective management of this complex condition.
20 02 2026
Read more
Revolutionary Blood Tests for Early Skin Cancer Detection in 2026
Discover revolutionary blood tests for early skin cancer detection in 2026. Learn how the Galleri test works and its accuracy...
20 02 2026
Read more
Unlocking Precision in CSU Management: The Role of Biomarkers
Discover how biomarkers enhance CSU management. Learn which factors predict treatment response for chronic spontaneous urticaria and improve patient outcomes.
19 02 2026
Read more
South Beach Symposium 2026: Innovations in Medical and Aesthetic Skin Care
Discover the latest innovations in medical and aesthetic skin care at the 2026 South Beach Symposium. Join experts as they...
17 02 2026
Read more
Rezpegaldesleukin Demonstrates Long-Term Efficacy in Atopic Dermatitis Trial
Discover the long-term efficacy of rezpegaldesleukin in treating moderate-to-severe atopic dermatitis, as revealed in the groundbreaking REZOLVE-AD trial results.
16 02 2026
Read more